Literature DB >> 23313086

Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.

K Hussein1, A Raz-Pasteur, R Finkelstein, A Neuberger, Y Shachor-Meyouhas, I Oren, I Kassis.   

Abstract

BACKGROUND: Carbapenem-resistant Enterobacteriaceae, especially Klebsiella spp., have become a major health problem recently worldwide. Since 2006 the incidence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections has increased substantially in Israel. Bloodstream infections (BSIs) caused by these strains have been associated with high rates of treatment failure and mortality. AIM: This study was designed to identify risk factors for carbapenem resistance among patients with healthcare-related (HCR) K. pneumoniae bacteraemia and predictors of mortality associated with HCR-CRKP bacteraemia compared with carbapenem-susceptible K. pneumoniae (CSKP).
METHODS: In this retrospective case-control study, all cases of K. pneumoniae bacteraemia during 2006-2008 were identified. Resistance patterns, underlying morbidities, risk factors for drug resistance and mortality rates were compared for patients with CRKP and CSKP bacteraemia.
FINDINGS: Two hundred and fourteen patients with CSKP bacteraemia were compared with 103 patients with CRKP bacteraemia. Severe, chronic comorbidities and prior antibiotic use were more frequent among patients with CRKP bacteraemia. On multivariate analysis prior use of macrolides and antibiotic exposure for ≥14 days remained the only independent factors associated with CRKP bacteraemia. Mortality rates of CRKP patients were significantly higher than those of CSKP patients. On multivariate analyses: bedridden status, chronic liver disease, Charlson comorbidity index ≥5, mechanical ventilation, and haemodialysis remained independently associated with mortality among patients with K. pneumoniae bacteraemia. Carbapenem resistance was not a risk factor for mortality.
CONCLUSIONS: Previous antibiotic exposure is a risk factor for CRKP-BSI. Mortality among patients with K. pneumoniae bacteraemia is associated with serious comorbidities, but not with carbapenem resistance.
Copyright © 2012 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23313086     DOI: 10.1016/j.jhin.2012.10.012

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  53 in total

1.  Implications of direct amplification for measuring antimicrobial resistance using point-of-care devices.

Authors:  M R Williams; R D Stedtfeld; H Waseem; T Stedtfeld; B Upham; W Khalife; B Etchebarne; M Hughes; J M Tiedje; S A Hashsham
Journal:  Anal Methods       Date:  2017-01-31       Impact factor: 2.896

2.  Characteristics and management of Enterobacteriaceae harboring IMP-4 or IMP-8 carbapenemase in a tertiary hospital.

Authors:  Feng Pang; Xiu-Qin Jia; Zhen-Zhu Song; Yan-Hua Li; Bin Wang; Qi-Gang Zhao; Chuan-Xin Wang; Yi Zhang; Le-Xin Wang
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

Review 3.  Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies.

Authors:  Stephanie M Pouch; Michael J Satlin
Journal:  Virulence       Date:  2016-07-28       Impact factor: 5.882

Review 4.  Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Thomas J Walsh
Journal:  Transpl Infect Dis       Date:  2017-10-25       Impact factor: 2.228

5.  Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.

Authors:  Pranita D Tamma; Katherine E Goodman; Anthony D Harris; Tsigereda Tekle; Ava Roberts; Abimbola Taiwo; Patricia J Simner
Journal:  Clin Infect Dis       Date:  2016-11-09       Impact factor: 9.079

6.  A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.

Authors:  Karlijn van Loon; Anne F Voor In 't Holt; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 7.  The opposing forces of the intestinal microbiome and the emerging pathobiome.

Authors:  Jennifer Defazio; Irma D Fleming; Baddr Shakhsheer; Olga Zaborina; John C Alverdy
Journal:  Surg Clin North Am       Date:  2014-10-07       Impact factor: 2.741

8.  Risk factors for hospital-acquired bloodstream infections caused by extended-spectrum β-lactamase Klebsiella pneumoniae among cancer patients.

Authors:  D Li; Y Chen; W Zhang; S Zheng; Q Zhang; C Bai; P Zhang
Journal:  Ir J Med Sci       Date:  2013-11-29       Impact factor: 1.568

9.  Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients.

Authors:  M P Freire; L C Pierrotti; H H C Filho; K Y Ibrahim; A S G K Magri; P R Bonazzi; L Hajar; M P E Diz; J Pereira; P M Hoff; E Abdala
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-30       Impact factor: 3.267

Review 10.  The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.

Authors:  Thomas M Baker; Michael J Satlin
Journal:  Leuk Lymphoma       Date:  2016-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.